Reviewing Sarepta Therapeutics Inc. (SRPT)’s and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK)’s results

Both Sarepta Therapeutics Inc. (NASDAQ:SRPT) and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sarepta Therapeutics Inc. 273.90M 33.62 245.02M -3.75 0.00
Merrimack Pharmaceuticals Inc. N/A 0.00 59.72M -2.98 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Sarepta Therapeutics Inc. and Merrimack Pharmaceuticals Inc.


Table 2 represents Sarepta Therapeutics Inc. (NASDAQ:SRPT) and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Sarepta Therapeutics Inc. -89.46% -33.7% -19.5%
Merrimack Pharmaceuticals Inc. 0.00% -58.4% -44.6%

Volatility and Risk

A beta of 1.84 shows that Sarepta Therapeutics Inc. is 84.00% more volatile than Standard & Poor’s 500. Merrimack Pharmaceuticals Inc.’s 125.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 2.25 beta.


Meanwhile, Merrimack Pharmaceuticals Inc.’s annual dividend is $10.55 per share and it also boasts of a 177.31% dividend yield. No dividend is paid out for Sarepta Therapeutics Inc.

Analyst Recommendations

Sarepta Therapeutics Inc. and Merrimack Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sarepta Therapeutics Inc. 0 0 5 3.00
Merrimack Pharmaceuticals Inc. 0 1 0 2.00

Sarepta Therapeutics Inc.’s consensus price target is $190.4, while its potential upside is 45.80%. Merrimack Pharmaceuticals Inc. on the other hand boasts of a $4 consensus price target and a -32.89% potential downside. The data from earlier shows that analysts opinion suggest that Sarepta Therapeutics Inc. seems more appealing than Merrimack Pharmaceuticals Inc.

Institutional and Insider Ownership

Roughly 93.3% of Sarepta Therapeutics Inc. shares are owned by institutional investors while 48.5% of Merrimack Pharmaceuticals Inc. are owned by institutional investors. 5.7% are Sarepta Therapeutics Inc.’s share owned by insiders. Competitively, Merrimack Pharmaceuticals Inc. has 4.05% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sarepta Therapeutics Inc. -5.15% -14.76% -12.41% 25.28% 128.59% 120.7%
Merrimack Pharmaceuticals Inc. -2.52% -10.32% -27.3% -52.08% -59.35% -58.44%

For the past year Sarepta Therapeutics Inc. has 120.7% stronger performance while Merrimack Pharmaceuticals Inc. has -58.44% weaker performance.


Sarepta Therapeutics Inc. beats Merrimack Pharmaceuticals Inc. on 8 of the 12 factors.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and CharleyÂ’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. Its therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.